WILLIAMS JOHN B
Known title: DirectorCIK: 0001291523
Associated companies
Transaction History
| ASB | ▲ Buy | Grant | 345 | $10K | 9/15/2026 | View on chart |
| ASB | ▲ Buy | Grant | 36 | $1K | 9/15/2026 | View on chart |
| ASB | ▲ Buy | Grant | 38 | $1K | 6/15/2026 | View on chart |
| ASB | ▲ Buy | Grant | 355 | $10K | 6/15/2026 | View on chart |
| ASB | ▼ Sell | Open Market | 4,000 | $113K | 4/28/2026 | View on chart |
| ASB | ▲ Buy | Grant | 417 | $10K | 3/16/2026 | View on chart |
| ASB | ▲ Buy | Grant | 44 | $1K | 3/16/2026 | View on chart |
| ASB | ▼ Sell | Open Market | 2,325 | $65K | 2/3/2026 | View on chart |
| ASB | ▲ Buy | Grant | 4,585 | $125K | 2/1/2026 | View on chart |
| ASB | ▲ Buy | Grant | 45 | $1K | 12/15/2025 | View on chart |
| ASB | ▲ Buy | Grant | 377 | $10K | 12/15/2025 | View on chart |
| ASB | ▲ Buy | Grant | 45 | $1K | 9/15/2025 | View on chart |
| ASB | ▲ Buy | Grant | 372 | $10K | 9/15/2025 | View on chart |
| ASB | ▲ Buy | Grant | 50 | $1K | 6/16/2025 | View on chart |
| ASB | ▲ Buy | Grant | 417 | $10K | 6/16/2025 | View on chart |
| ASB | ▲ Buy | Grant | 51 | $1K | 3/17/2025 | View on chart |
| ASB | ▲ Buy | Grant | 427 | $9K | 3/17/2025 | View on chart |
| ASB | ▼ Sell | Open Market | 2,830 | $71K | 2/14/2025 | View on chart |
| ASB | ▲ Buy | Grant | 4,972 | $125K | 2/1/2025 | View on chart |
| ASB | ▲ Buy | Grant | 55 | $1K | 12/16/2024 | View on chart |
| ASB | ▲ Buy | Grant | 366 | $9K | 12/16/2024 | View on chart |
| ASB | ▲ Buy | Grant | 63 | $1K | 9/16/2024 | View on chart |
| ASB | ▲ Buy | Grant | 416 | $9K | 9/16/2024 | View on chart |
| ASB | ▲ Buy | Grant | 65 | $1K | 6/17/2024 | View on chart |
| ASB | ▲ Buy | Grant | 436 | $9K | 6/17/2024 | View on chart |
| ASB | ▲ Buy | Grant | 65 | $1K | 3/15/2024 | View on chart |
| ASB | ▲ Buy | Grant | 431 | $9K | 3/15/2024 | View on chart |
| ASB | ▼ Sell | Open Market | 2,271 | $44K | 2/7/2024 | View on chart |
| ASB | ▼ Sell | Open Market | 429 | $8K | 2/7/2024 | View on chart |
| ASB | ▲ Buy | Grant | 5,998 | $125K | 2/1/2024 | View on chart |
| ASB | ▲ Buy | Grant | 59 | $1K | 12/15/2023 | View on chart |
| ASB | ▲ Buy | Grant | 407 | $9K | 12/15/2023 | View on chart |
| ASB | ▲ Buy | Grant | 66 | $1K | 9/15/2023 | View on chart |
| ASB | ▲ Buy | Grant | 462 | $8K | 9/15/2023 | View on chart |
| ASB | ▲ Buy | Grant | 67 | $1K | 6/15/2023 | View on chart |
| ASB | ▲ Buy | Grant | 534 | $9K | 6/15/2023 | View on chart |
| ASB | ▲ Buy | Grant | 414 | $8K | 3/15/2023 | View on chart |
| ASB | ▲ Buy | Grant | 60 | $1K | 3/15/2023 | View on chart |
| ASB | ▼ Sell | Open Market | 1,440 | $34K | 2/7/2023 | View on chart |
| ASB | ▼ Sell | Open Market | 400 | $10K | 2/7/2023 | View on chart |
| ASB | ▲ Buy | Grant | 5,499 | $125K | 2/1/2023 | View on chart |
| ASB | ▲ Buy | Grant | 47 | $1K | 12/15/2022 | View on chart |
| ASB | ▲ Buy | Grant | 355 | $8K | 12/15/2022 | View on chart |
| ASB | ▲ Buy | Grant | 352 | $7K | 9/15/2022 | View on chart |
| ASB | ▲ Buy | Grant | 47 | $993 | 9/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Barclays Raises ASB Price Target to $35, Maintains Overweight
Barclays has raised its price target for Associated Banc-Corp to $35 while maintaining an Overweight rating. This move aligns with the broader analyst consensus, where the average target is $34.20. The stock is currently trading near its 52-week high, reflecting recent strength compared to some finance peers. Investors are also awaiting the company's third-quarter earnings report scheduled for late October.
Barclays Raises ASB Price Target to $35, Maintains Overweight. Barclays has raised its price target for Associated Banc-Corp to $35 while maintaining an Overweight rating. This move aligns with the broader analyst consensus, where the average target is $34.20. The stock is currently trading near its 52-week high, reflecting recent strength compared to some finance peers. Investors are also awaiting the company's third-quarter earnings report scheduled for late October.